16078-42-5 Usage
Description
1-(2-methyl-3,4-dihydroquinolin-1(2H)-yl)ethanone is a chemical compound with the molecular formula C12H15NO. It is a derivative of quinolinone and is commonly used in the pharmaceutical and chemical industries. 1-(2-methyl-3,4-dihydroquinolin-1(2H)-yl)ethanone is known for its potential biological activities and is of interest as a building block in the synthesis of various pharmaceutical compounds.
Uses
Used in Pharmaceutical Industry:
1-(2-methyl-3,4-dihydroquinolin-1(2H)-yl)ethanone is used as a building block for the synthesis of pharmaceutical compounds due to its potential biological activities and chemical properties.
Used in Medicinal Chemistry:
1-(2-methyl-3,4-dihydroquinolin-1(2H)-yl)ethanone is used as a compound of interest in the field of medicinal chemistry for its potential applications in drug discovery and development.
Used in Drug Production:
1-(2-methyl-3,4-dihydroquinolin-1(2H)-yl)ethanone is used as a key component in the production of a wide range of drugs, contributing to the development of new therapeutic options.
Ongoing Research:
1-(2-methyl-3,4-dihydroquinolin-1(2H)-yl)ethanone is currently under research to explore its potential therapeutic uses and further applications in drug discovery and development, which may lead to new advancements in the pharmaceutical and medical fields.
Check Digit Verification of cas no
The CAS Registry Mumber 16078-42-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,0,7 and 8 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 16078-42:
(7*1)+(6*6)+(5*0)+(4*7)+(3*8)+(2*4)+(1*2)=105
105 % 10 = 5
So 16078-42-5 is a valid CAS Registry Number.
16078-42-5Relevant articles and documents
DUAL KINASE-BROMODOMAIN INHIBITORS
-
Page/Page column 89; 112, (2021/12/12)
Provided herein are compounds of Formula (I) that are dual inhibitors of kinases and bromo-domain proteins. The disclosure also relates to pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of cancers, particularly, the treatment of multiple myeloma cancers, and to related uses.
NOVEL PROCESS
-
Paragraph 0126; 0127, (2015/12/31)
A compound or a pharmaceutically acceptable salt or solvate thereof with a molecular weight in the range 100 to 750 which inhibits the binding of the first and/or second bromodomains of human BRD-2 to 4 to acetylated lysine residues of their physiological partner which is able to: a) form a hydrogen bonding interaction in which the compound accepts a hydrogen bond from the sidechain NH2 group of the asparagine residue found at: or b) accept a water-mediated hydrogen bond in which the compound accepts a hydrogen bond from a water that is itself hydrogen-bonded to the sidechain hydroxyl of the tyrosine residue found at and c) which are also able to form a Van der Waals interaction with a lipophilic binding region of a binding pocket such that one or more heavy atoms of the said compounds lie within a 5A range of any of the heavy atoms of the following bromodomain residues which define the binding pocket: for use in the treatment of chronic autoimmune and inflammatory conditions, acute inflammatory conditions or cancer.